- Title: Subtitle
- Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC)
- Creators
- Carryn M. Anderson - University of IowaBryan G. Allen - University of IowaWenqing Sun - University of IowaSanjiv S. Agarwala - St. Luke's Medical CenterChristopher M. Lee - Cancer Care NorthwestMadhavi L. Venigalla - Lakeland Regional Medical CenterLarisa Greenberg - Allegheny General HospitalDouglas Adkins - Washington University in St. LouisYuhchyau Chen - University of Rochester Medical CenterWeining Zhen - University of Nebraska Medical CenterDiane R. Mould - Projections Research Inc., Phoenixville, PA;Jon Holmlund - Galera Therapeutics, Inc, Malvern, PA;Jeffrey Mark Brill - Galera Therapeutics, Inc, Malvern, PA;Stephen T. Sonis - BioModels, Boston, MA;John Michael Buatti - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.34(15_suppl), pp.10120-10120
- DOI
- 10.1200/JCO.2016.34.15_suppl.10120
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2016
- Academic Unit
- Neurosurgery; Otolaryngology; Radiation Oncology
- Record Identifier
- 9984314295902771
Abstract
Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC)
Journal of clinical oncology, Vol.34(15_suppl), pp.10120-10120
05/20/2016
DOI: 10.1200/JCO.2016.34.15_suppl.10120
Details
Metrics
7 Record Views